Roman Butler Fullerton & Co. Acquires 76,121 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Roman Butler Fullerton & Co. grew its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 241.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 107,626 shares of the biotechnology company’s stock after purchasing an additional 76,121 shares during the quarter. Roman Butler Fullerton & Co.’s holdings in ADMA Biologics were worth $2,151,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of ADMA. Quest Partners LLC bought a new position in ADMA Biologics during the second quarter valued at about $29,000. EntryPoint Capital LLC bought a new position in shares of ADMA Biologics in the 1st quarter valued at approximately $31,000. USA Financial Formulas raised its stake in shares of ADMA Biologics by 8.6% in the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 539 shares in the last quarter. CWM LLC lifted its holdings in ADMA Biologics by 114.2% in the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 4,367 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new stake in ADMA Biologics during the second quarter worth approximately $93,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Insider Activity

In related news, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the sale, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now owns 153,941 shares of the company’s stock, valued at $2,843,290.27. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the transaction, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 466,900 shares of company stock valued at $8,224,121. Insiders own 3.70% of the company’s stock.

ADMA Biologics Stock Up 18.8 %

Shares of ADMA stock opened at $19.37 on Monday. ADMA Biologics, Inc. has a 12 month low of $3.40 and a 12 month high of $21.13. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. The firm has a market cap of $4.51 billion, a PE ratio of 138.36 and a beta of 0.64. The stock has a 50 day moving average of $17.85 and a 200-day moving average of $13.46.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.08 by $0.05. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The firm had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. During the same period in the prior year, the company earned ($0.02) EPS. The business’s quarterly revenue was up 78.4% compared to the same quarter last year. On average, equities analysts predict that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

Analyst Ratings Changes

ADMA has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of ADMA Biologics in a research report on Monday, October 14th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, ADMA Biologics currently has a consensus rating of “Buy” and an average price target of $15.50.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.